Crescent Biopharma
CBIO
35 hedge funds and large institutions have $6.46M invested in Crescent Biopharma in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 12 closing their positions.
0.01% more ownership
Funds ownership: 0.47% → 0.48% (+0.01%)
15% less capital invested
Capital invested by funds: $7.56M → $6.46M (-$1.1M)
15% less funds holding
Funds holding: 41 → 35 (-6)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
54% less call options, than puts
Call options by funds: $24K | Put options by funds: $52K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$102K |
| 2 |
SC
Shay Capital
New York
|
+$95.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$63.4K |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$43.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$82.6K |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$50.9K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$16K |
| 4 |
Jane Street
New York
|
-$14.7K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.5K |
CBIO Hedge Fund Activity: Q1 2025 in Review
35 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2025, worth a combined $6.46M — down 15% from $7.56M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CBIO and 6 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $102K. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $82.6K sold.
- 35 institutional investors held Crescent Biopharma (CBIO) as of Q1 2025, down from 41 in Q4 2024.
- Funds reported $6.46M of Crescent Biopharma stock for Q1 2025, down 15% quarter-over-quarter.
- 6 funds opened new Crescent Biopharma positions in Q1 2025 and 12 closed out, a net change of -6 holders.
- The largest Crescent Biopharma buyer in Q1 2025 was Balyasny Asset Management, an estimated $102K added.
- The largest Crescent Biopharma seller in Q1 2025 was ADAR1 Capital Management, an estimated $82.6K sold.
Based on aggregated 13F filings for Q1 2025.